GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Return-on-Tangible-Asset

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Return-on-Tangible-Asset : -68.56% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Quoin Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2024 was $-9.31 Mil. Quoin Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2024 was $13.58 Mil. Therefore, Quoin Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -68.56%.

The historical rank and industry rank for Quoin Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

QNRX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -476.27   Med: -267.34   Max: -55.76
Current: -55.76

During the past 5 years, Quoin Pharmaceuticals's highest Return-on-Tangible-Asset was -55.76%. The lowest was -476.27%. And the median was -267.34%.

QNRX's Return-on-Tangible-Asset is ranked worse than
61.06% of 1546 companies
in the Biotechnology industry
Industry Median: -40.51 vs QNRX: -55.76

Quoin Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Quoin Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals Return-on-Tangible-Asset Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
- -450.54 -476.27 -84.13 -68.57

Quoin Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.06 -49.83 -50.55 -63.01 -68.56

Competitive Comparison of Quoin Pharmaceuticals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Quoin Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quoin Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Return-on-Tangible-Asset falls into.



Quoin Pharmaceuticals Return-on-Tangible-Asset Calculation

Quoin Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-8.687/( (13.753+11.586)/ 2 )
=-8.687/12.6695
=-68.57 %

Quoin Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-9.308/( (11.586+15.565)/ 2 )
=-9.308/13.5755
=-68.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Quoin Pharmaceuticals  (NAS:QNRX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Quoin Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper director PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell director C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn officer: Chief Financial Officer AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter director, officer: Chief Operating Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers director, officer: Chief Executive Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines